Orphazyme trended on social media in the US on Thursday as its share price rocketed for no clear reason.
The biotech company has also attracted attention in Denmark, where the share price rose by 40 percent up to DKK 47.6 on Friday – a significant increase, but far less than the rise in the US.
More from MedWatch
Experiences from Danish climate partnerships are among the tools that can be leveraged when Novo Nordisk CEO Lars Fruergaard begins stepping up efforts in the life science sector’s central organs in Brussels. ”I’ve been fired up by the intimacy and shared vision we could see in Denmark,” he tells MedWatch.